Hims & Hers Health Stock Soared This Week: Here's Why
Hims & Hers recently launched weight loss drugs at a disruptive price point. The company is growing revenue quickly.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Ultimate Growth Stock to Buy With $20 Right Now
Hims & Hers has entered the popular GLP-1 agonist category. Weight loss has quickly become a significant, potentially unexpected catalyst.
Hims & Hers Is Changing the Game
GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.
Hims & Hers rolls out weight-loss shots much cheaper than Ozempic, Wegovy
Health and wellness company Hims & Hers announced Monday that it is introducing injectable weight-loss drugs at a fraction of the cost of Ozempic and Wegovy.
Weight loss drug roll-out sends Hims & Hers stock soaring
Weight loss drugs helped Hims & Hers Health (NYSE:HIMS) put value on, with the stock soaring some 30% higher in ‘afterhours' trade on Monday. The online consumer healthcare brand last night announced it will sell lower-priced GLP-1 weight loss injectables and oral weight loss medication in the United States, through a deal with its pharmacy supplier.
Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy
Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk's Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments.
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
Shares of Hims & Hers Health (NYSE: HIMS ) stock are skyrocketing higher by over 25% after the telehealth company announced that it would provide access to GLP-1 weight-loss injections. Hims & Hers has partnered with an undisclosed manufacturer of generic and 503B compounded injectable medications to provide the injections.
Hims & Hers Adds Weight-Loss Injections, Stock Soars
Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 29.4% to trade at $18.85 and earlier hitting a three-year high of $20.11.
Tech Surge Boosts Nasdaq to Record Highs
Tech Surge Boosts Nasdaq to Record Highs The S&P 500 is wavering below all-time highs as well Laura McCandless Deputy Editor May 20, 2024 at 11:48 AM SPX|IXIC|DJI All three major indexes are higher midday The Nasdaq Composite Index (IXIC) is up triple digits and marking new record highs, thanks to rising tech stocks. Nvidia (NVDA), specifically, is in focus as analysts throw in bull notes ahead of this week's earnings report. The Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) are enjoying more modest gains, though the latter is nearing its own all-time highs. Meanwhile, bond yields are also rising, amid comments from several Fed officials regarding inflation. Continue reading for more on today's market, including: Elliott built a $1 billion-plus stake in this electrical stock. Morgan Stanley upgrades Micron Technology stock. Plus, options traders target HIMS; DYN soars on trial data; and Li Auto's earnings disappoint. Options bulls are blasting Hims & Hers Health Inc (NYSE:HIMS), after the healthcare platform added GLP-1 injections to its weight-loss services, a compounded and cheap version of Novo Nordisk's (NVO) semaglutide (the active ingredient in Wegovy). So far, 100,000 calls have been exchanged -- 18 times the call volume typically seen at this point -- in comparison to 26,000 puts. The weekly 5/24 20-strike call is the most popular by far, where new positions are being opened. At last glance, HIMS was up 29.5% at $18.87, earlier hitting a three-year peak of $20.11. Dyne Therapeutics Inc (NASDAQ:DYN) is up 24.5% at $34.46 at last glance, after the biotech reported positive data for its muscular dystrophy treatments. In response, H.C. Wainwright raised its price target to $48 from $36, while Jefferies lifted its price objective to $42 from $36. Today's pop has DYN soaring to record highs, up 157.9% since the start of 2024. Meanwhile, the shares of Li Auto Inc (NASDAQ:LI) are trading at 52-week lows, down 14.1% at $21.37, after the China-based electric vehicle (EV) stock's disappointing first-quarter results. On the short sell restricted (SSR) list amid the volatility, LI is down roughly 43% year to date. Follow @Schaeffers (function () { var po = document.createElement('script'); po.type = 'text/javascript'; po.async = true; po.src = 'Click Here var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(po, s); })();
The case for the overvalued Hims & Hers stock
Hims & Hers Health (NYSE: HIMS) stock price is doing well, helped by its strong growth and demand for its core products. It soared by over 30% this year and by more than 112% this year.
Stock Market Mayhem: 3 Companies Ready to Shake Things Up
With the stock market heating up again, consider investing in disruptive stocks to buy. Betting on disruptive stocks, especially at the right prices, can prove incredibly rewarding.
